Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study.
European urology oncology, cilt.9, sa.1, ss.80-92, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 9 Sayı: 1
- Basım Tarihi: 2026
- Doi Numarası: 10.1016/j.euo.2025.09.010
- Dergi Adı: European urology oncology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
- Sayfa Sayıları: ss.80-92
- Anahtar Kelimeler: Abiraterone, Brief Pain Inventory-Short Form, Functional Assessment of Cancer Therapy-Prostate, Health-related quality of life, Metastatic castration-resistant prostate cancer, Olaparib, Patient-reported outcomes, PROpel trial
- İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet